Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”
Marco Picardi, Annamaria Vincenzi · 2026
Read Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?” by Marco Picardi, Annamaria Vincenzi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13530936.txt.
Description
Marco Picardi and Annamaria Vincenzi argue a dose case in Hodgkin lymphoma care in a 2026 comment. Front care for young adults with the classic form falls short, they open. New drug pairs lift cure rates and cut beam need. Yet heart harm from the red drug clan caps its use. Fresh marks set the harm line at 210 milligrams per square meter. Past it, one in seven face heart fail in 20 to 30 years.
Their case: a fat-wrapped form of the drug may let teams push dose with less heart risk. Heart scans with strain reads should guard the path. The piece is a stance in a live dose debate, not new trial data.
Catalog record
| CREATOR | Marco Picardi, Annamaria Vincenzi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |